

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CANbridge Pharmaceuticals Inc.

北海康成製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1228)

**CHANGE OF JOINT COMPANY SECRETARY AND
AUTHORISED REPRESENTATIVE
AND
WAIVER FROM STRICT COMPLIANCE WITH RULES 3.28 AND 8.17 OF
THE LISTING RULES**

The board of directors (the “**Board**”) of CANbridge Pharmaceuticals Inc. (the “**Company**”) hereby announces that Mr. Keith Shing Cheung Wong has tendered his resignation as the joint company secretary of the Company (the “**Joint Company Secretary**”) and has ceased to act as an authorised representative of the Company (the “**Authorised Representative**”) under Rule 3.05 of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) with effect from April 1, 2022.

Mr. Keith Shing Cheung Wong confirmed that he has no disagreement with the Board and there are no circumstances relating to his above resignations which need to be brought to the attention of the Stock Exchange or the shareholders of the Company.

Reference is made to the prospectus of the Company dated November 30, 2021 regarding the appointment of Ms. Qian Ma (“**Ms. Ma**”) as one of the Joint Company Secretaries and the waiver (the “**Waiver**”) granted to the Company by the Stock Exchange from strict compliance with the requirements under Rules 3.28 and 8.17 of the Listing Rules in relation to the eligibility of Ms. Ma to act as the Joint Company Secretary for a period of three years from the date of the Company’s listing (i.e. December 10, 2021) to December 9, 2024 (the “**Waiver Period**”), on the condition that Mr. Keith Shing Cheung Wong, who meets the requirements under Rules 3.28 and 8.17 of the Listing Rules, is engaged as the Joint Company Secretary and provides assistance to Ms. Ma to acquire the “relevant experience” within the meaning of Rule 3.28 of the Listing Rules and to discharge his duties as the Joint Company Secretary during the Waiver Period. The Waiver will be revoked immediately if Mr. Keith Shing Cheung Wong ceases to provide assistance to Ms. Ma.

In view of Mr. Keith Shing Cheung Wong's resignation and since Ms. Ma does not possess the qualifications of company secretary as required under Rule 3.28 of the Listing Rules, the Company has applied for, and the Stock Exchange has granted, a new waiver from strict compliance with Rules 3.28 and 8.17 of the Listing Rules (the "**New Waiver**") for a period from the date of appointment of Mr. Wai Chiu Wong ("**Mr. Wong**") to December 9, 2024 (the "**New Waiver Period**") on the conditions that (i) Ms. Ma will be assisted by Mr. Wong during the New Waiver Period and the New Waiver will be revoked immediately if and when Mr. Wong ceases to provide assistance to Ms. Ma; (ii) the New Waiver could be revoked if there are material breaches of the Listing Rules by the Company; and (iii) the Company will disclose details of the New Waiver, including the reasons for and the conditions of the New Waiver, and the qualification and experience of both Ms. Ma and Mr. Wong. In addition, the Company shall notify the Stock Exchange at the end of the New Waiver Period for the Stock Exchange to re-visit the situation, as the Stock Exchange expects that after the end of the New Waiver Period, the Company will be able to demonstrate that Ms. Ma can satisfy Rule 3.28 of the Listing Rules after having the benefit of Mr. Wong's assistance such that a further waiver will not be necessary.

The Board is pleased to further announce that Mr. Wong has been appointed as the Joint Company Secretary and the Authorised Representative with effect from April 1, 2022.

The biographical details of Ms. Ma and Mr. Wong are set out as follows:

Ms. Ma

Ms. Ma is the Head of Legal and Compliance of our Company. She has worked with King & Wood Mallesons since July 2015 and has supported the Company as designated external legal counsel since 2017, where she has facilitated legal and compliance of the Company. Ms. Ma has obtained the PRC legal professional qualification in 2014. She also obtained her bachelor's degree in history and international studies and her Juris Master degree from Peking University in July 2013 and July 2016, respectively.

Mr. Wong

Mr. Wong is the Associate Director of SWCS Corporate Services Group (Hong Kong) Limited. Mr. Wong has extensive experience in compliance and listed companies secretarial work.

Mr. Wong is a fellow of Hong Kong Chartered Governance Institute (previously known as Hong Kong Institute of Chartered Secretaries), a fellow of the Chartered Governance Institute, a member of CPA Australia, a member of the Hong Kong Trustee Association and a Certified Trust Practitioner.

Mr. Wong possesses a B. Soc. Sc. (Hon.) major in Accounting and Management from the University of Hong Kong, a Post-Graduate Diploma in HK and UK law from the Manchester Metropolitan University of United Kingdom, Master degree in Corporate Governance from the Hong Kong Polytechnic University, Master Degree in Arbitration and Dispute Resolution from City University of Hong Kong and Master of Applied Science (Information Science) Degree from the University of Technology, Sydney, Australia.

The Board would like to take this opportunity to express its sincere gratitude to Mr. Keith Shing Cheung Wong for his contribution to the Company during his tenure of service and welcome Mr. Wong on his new appointments.

By order of the Board
CANbridge Pharmaceuticals Inc.
Dr. James Qun Xue
Chairman

Hong Kong, April 1, 2022

As at the date of this announcement, the board of directors of the Company comprises Dr. James Qun Xue as executive director; Dr. Kan Chen, Dr. Derek Paul Di Rocco and Mr. Xiao Le as non-executive directors; and Mr. James Arthur Geraghty, Dr. Richard James Gregory, Mr. Peng Kuan Chan and Dr. Lan Hu as independent non-executive directors.